Showing results (1951-1960 of 2,161) with videos related to
Sort By:
Pageof 217
Healthcare (Amsterdam, Netherlands)|May 16, 2025
One cutoff is not enough: Assessing different area deprivation index cutoffs for insurance types on surgical Desirability of Outcome Ranking (DOOR)Susanne Schmidt, Michael A Jacobs, Daniel E Hall, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphomaSamuel A Jacobs, Steven H Swerdlow, Jeffrey Kant, et al.British Journal of Sports Medicine|July 14, 2012
The role of haemoglobin mass on VO(2)max following normobaric 'live high-train low' in endurance-trained athletesPaul Robach, Christoph Siebenmann, Robert A Jacobs, et al.Journal of the American Heart Association|January 19, 2024
Association Between Self-Reported Medication Adherence and Therapeutic Inertia in Hypertension: A Secondary Analysis of SPRINT (Systolic Blood Pressure Intervention Trial)Joshua A Jacobs, Catherine G Derington, Alexander R Zheutlin, et al.Sports Health|March 4, 2024
Sex Differences in Quadriceps Atrophy After Anterior Cruciate Ligament TearMeredith K Owen, Kelsey R Casadonte, Nicholas T Thomas, et al.Proceedings of the National Academy of Sciences of the United States of America|November 18, 2003
Comprehensive transposon mutant library of Pseudomonas aeruginosaMichael A Jacobs, Ashley Alwood, Iyarit Thaipisuttikul, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Randomized trial of influenza vaccine with granulocyte-macrophage colony-stimulating factor or placebo in cancer patientsRamesh K Ramanathan, Douglas M Potter, Chandra P Belani, et al.The Lancet. Oncology|October 17, 2017
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trialTomasz M Beer, Sebastien J Hotte, Fred Saad, et al.Journal of the American Heart Association|August 30, 2023
New Users of Angiotensin II Receptor Blocker-Versus Angiotensin-Converting Enzyme Inhibitor-Based Antihypertensive Medication Regimens and Cardiovascular Disease Events: A Secondary Analysis of ACCORD-BP and SPRINTJordan B King, Ransmond O Berchie, Catherine G Derington, et al.Medicine and Science in Sports and Exercise|March 15, 2006
Cytokine responses at high altitude: effects of exercise and antioxidants at 4300 mTodd A Hagobian, Kevin A Jacobs, Andrew W Subudhi, et al.Pageof 217